Humulin S (Soluble) (Insulin Human (Rdna))

Humulin S (Soluble) is a recombinant human insulin (Insulin human, rDNA) supplied as an injectable solution for subcutaneous administration. It is a prescription‑only product marketed in the European Union. The formulation provides rapid‑acting insulin to replace or supplement endogenous insulin in patients with diabetes mellitus. Humulin S is used under medical supervision to help control blood glucose levels and is typically prescribed as part of a comprehensive diabetes management plan.

Humulin S is indicated for the treatment of diabetes mellitus where insulin therapy is required.

- Type 1 diabetes mellitus (absolute insulin deficiency). - Type 2 diabetes mellitus (insulin insufficiency or resistance). - Management of hyperglycemia during pregnancy (gestational diabetes) when oral agents are unsuitable. - Use in diabetic ketoacidosis as part of insulin replacement therapy. - Adjunct to dietary control and exercise to achieve target glycemic levels.

Like all insulin preparations, Humulin S may cause adverse reactions, ranging from mild to severe.

Common: - Hypoglycemia (low blood glucose). - Injection‑site redness, swelling, or pain. - Lipodystrophy at injection sites. - Weight gain. - Mild allergic skin rash.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Anaphylactic reaction. - Hypokalemia. - Edema or fluid retention. - Development of insulin antibodies causing resistance.

Healthcare providers should consider several precautions when prescribing Humulin S to ensure safe and effective use.

- Regular monitoring of blood glucose and adjusting dose as needed. - Dose adjustments may be required in renal or hepatic impairment. - Caution in patients with hypoglycemia unawareness. - Use only if benefits outweigh potential risks during pregnancy or lactation. - Monitor serum potassium levels, especially if on diuretics. - Educate patients on proper injection technique and site rotation. - Assess cardiovascular status, as rapid glucose changes can affect heart function.

Humulin S can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Beta‑blockers (may mask hypoglycemia symptoms). - Monoamine oxidase inhibitors (potentiate hypoglycemia). - Oral hypoglycemic agents (additive glucose‑lowering effect).

Use with caution: - Corticosteroids (increase blood glucose, may require higher insulin dose). - Thiazide diuretics (may raise glucose levels). - ACE inhibitors (can enhance insulin sensitivity). - Alcohol (risk of delayed hypoglycemia).